Hemolytic uremic syndrome (HUS) is a thrombotic microangiopathy (TMA) defined by the
clinical triad of thrombocytopenia, microangiopathic hemolytic anemia (MAHA) and renal …

Shiga-like toxin-1 and Shiga-like toxin-2 regulate genes that encode for chemokines,
cytokines, cell adhesion molecules, and transcription factors involved in immune response …

A typical hemolytic uremic syndrome (aHUS) presents similarly to thrombotic
thrombocytopenic purpura (TTP) and other causes or conditions with thrombotic …

Atypical hemolytic uremic syndrome (aHUS) is a rare syndrome of hemolysis,
thrombocytopenia, and renal insufficiency. Genetic mutations in the alternate pathway of …

Objectives: Thrombotic microangiopathy syndromes are a heterogeneous group of severe
diseases that often require ICU admission. Prompt initiation of targeted therapies is required …

Atypical hemolytic uremic syndrome (aHUS) is a rare life‐threatening thrombotic
microangiopathy (TMA) affecting multiple organ systems. Recently, aHUS has been shown …

Objective: Rare disease Background: Atypical hemolytic uremic syndrome (aHUS) is a rare
disease characterized by hemolysis, thrombocytopenia, and renal dysfunction. It is a …

The hemolytic uremic syndrome (HUS) is classified as a rare disease, but Shiga toxin-
producing Escherichia coli (STEC)-HUS and atypical HUS are often encountered in children …

Atypical hemolytic uremic syndrome (aHUS) is now well recognized to be a disease
characterized by excessive complement activation in the microvasculature. In both the …

The term thrombotic microangiopathy (TMA) has been used to describe multiple disease
entities characterized by endothelial injury, thrombus formation, and resultant …